Braidwell LP Makes New Investment in Sarepta Therapeutics, Inc. $SRPT

Braidwell LP bought a new position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 832,100 shares of the biotechnology company’s stock, valued at approximately $16,035,000. Braidwell LP owned approximately 0.79% of Sarepta Therapeutics as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently modified their holdings of SRPT. Vanguard Group Inc. increased its position in Sarepta Therapeutics by 18.1% during the third quarter. Vanguard Group Inc. now owns 10,817,446 shares of the biotechnology company’s stock worth $208,452,000 after acquiring an additional 1,657,267 shares during the period. First Trust Advisors LP boosted its holdings in Sarepta Therapeutics by 209.1% in the 3rd quarter. First Trust Advisors LP now owns 1,939,781 shares of the biotechnology company’s stock valued at $37,380,000 after purchasing an additional 1,312,220 shares during the period. Connor Clark & Lunn Investment Management Ltd. boosted its holdings in Sarepta Therapeutics by 183.5% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 1,745,051 shares of the biotechnology company’s stock valued at $33,627,000 after purchasing an additional 1,129,610 shares during the period. Erste Asset Management GmbH grew its position in shares of Sarepta Therapeutics by 65.7% during the 3rd quarter. Erste Asset Management GmbH now owns 2,685,945 shares of the biotechnology company’s stock worth $50,588,000 after purchasing an additional 1,064,530 shares in the last quarter. Finally, Federated Hermes Inc. grew its position in shares of Sarepta Therapeutics by 347.8% during the 2nd quarter. Federated Hermes Inc. now owns 1,308,199 shares of the biotechnology company’s stock worth $22,370,000 after purchasing an additional 1,016,069 shares in the last quarter. Institutional investors own 86.68% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on SRPT. HC Wainwright reiterated a “sell” rating on shares of Sarepta Therapeutics in a research report on Monday, March 2nd. Mizuho increased their price target on Sarepta Therapeutics from $26.00 to $31.00 and gave the stock an “outperform” rating in a research report on Thursday. Wedbush lowered their price objective on Sarepta Therapeutics from $34.00 to $29.00 and set an “outperform” rating on the stock in a research note on Monday, March 2nd. Loop Capital set a $25.00 price objective on Sarepta Therapeutics in a report on Tuesday, March 3rd. Finally, Jefferies Financial Group reiterated a “buy” rating and set a $30.00 target price on shares of Sarepta Therapeutics in a research report on Tuesday, March 3rd. Nine equities research analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and six have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $32.15.

Sarepta Therapeutics Stock Down 3.8%

NASDAQ SRPT opened at $16.40 on Friday. The business has a fifty day moving average price of $19.43 and a two-hundred day moving average price of $19.99. The stock has a market capitalization of $1.72 billion, a PE ratio of -1.94, a PEG ratio of 0.24 and a beta of 0.42. Sarepta Therapeutics, Inc. has a fifty-two week low of $10.41 and a fifty-two week high of $103.32. The company has a debt-to-equity ratio of 0.73, a current ratio of 2.32 and a quick ratio of 1.48.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported ($3.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.87) by ($2.71). Sarepta Therapeutics had a negative net margin of 38.34% and a negative return on equity of 50.74%. The business had revenue of $442.93 million during the quarter, compared to the consensus estimate of $390.95 million. During the same quarter in the previous year, the business posted $1.90 EPS. The company’s revenue for the quarter was down 32.7% on a year-over-year basis. Equities analysts expect that Sarepta Therapeutics, Inc. will post 2.67 earnings per share for the current fiscal year.

Insider Activity

In other Sarepta Therapeutics news, Director Stephen Mayo sold 7,239 shares of the business’s stock in a transaction dated Thursday, March 12th. The stock was sold at an average price of $17.02, for a total transaction of $123,207.78. Following the completion of the transaction, the director owned 1,765 shares of the company’s stock, valued at approximately $30,040.30. The trade was a 80.40% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Ian Michael Estepan sold 13,187 shares of the stock in a transaction dated Tuesday, December 16th. The stock was sold at an average price of $22.31, for a total transaction of $294,201.97. Following the completion of the transaction, the chief operating officer directly owned 193,300 shares of the company’s stock, valued at $4,312,523. This trade represents a 6.39% decrease in their position. The SEC filing for this sale provides additional information. 7.60% of the stock is currently owned by insiders.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.